According to the international medical announcement, the company received an audit inquiry letter from the Shenzhen Stock Exchange on May 12, 2026 regarding the issuance of shares to specific targets, and on June 13, it worked with intermediaries to respond to the inquiry letter and update the application documents. Recently, based on further review opinions from the Shenzhen Stock Exchange, the company once again added, updated and revised the content of the response and application documents. The offering has yet to be reviewed by the Shenzhen Stock Exchange and approved for registration by the China Securities Regulatory Commission. The results and timing are uncertain.

According to the international medical announcement, the company received an audit inquiry letter from the Shenzhen Stock Exchange on May 12, 2026 regarding the issuance of shares to specific targets, and on June 13, it worked with intermediaries to respond to the inquiry letter and update the application documents. Recently, based on further review opinions from the Shenzhen Stock Exchange, the company once again added, updated and revised the content of the response and application documents. The offering has yet to be reviewed by the Shenzhen Stock Exchange and approved for registration by the China Securities Regulatory Commission. The results and timing are uncertain.